HemaCare Corp. has acquired privately owned Teragenix Corp. for $4.8 million. Teragenix, which had 2005 sales of $5 million and pre-tax profit of about $600,000, is a provider of human biological samples, quality control products and clinical trial management services. The acquisition represents a significant step in furthering HemaCare’s strategy to expand product and service offerings for biotechnology, pharmaceutical and other research-focused organizations, according to a company state...